News Summary: FDA backs early-stage cancer drug

ACCELERATED APPROVAL: Government scientists on Tuesday recommended speedy approval for a Roche breast cancer drug that could become the first pharmaceutical product approved for use before surgery.

NEW OPTION: Preliminary results submitted by Roche showed that women who received the drug Perjeta were more likely to be cancer-free than women receiving older drug combinations.

COMMITTEE OPINION: On Thursday, the FDA will ask an outside panel of cancer specialists whether Perjeta’s benefits outweigh its risks for treating early-stage breast cancer. The vote is non-blinding but factors into the FDA’s decision. provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language, racial slurs or consistent name calling will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review.

blog comments powered by Disqus